Drug eluting stents for the treatment of bare metal in-stent restenosis: Long-term outcomes in real world practice

EuroIntervention

Volumn 6, Issue 6, 2011, Pages 748-753

  Appleby, Clare E ^a   Khattar, Raj S ^a   Morgan, Kenneth ^a   Clarke, Bernard ^a   Curzen, Nicholas ^b   Neyses, Ludwig ^a   Fath Ordoubadi, Farzin ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical outcomes; Drug eluting stents; In stent restenosis; MACE

Indexed keywords

'TAXUS'; CYPHER; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ARTICLE; BARE METAL STENT; CARDIOGENIC SHOCK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; REVASCULARIZATION; TARGET LESION REVASCULARIZATION; TREATMENT RESPONSE;

AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; ENGLAND; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954542332     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I6A127     Document Type: Article

References (20)

1. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:12602-4.
2. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, Schomig A. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004;147:317-22. (Pubitemid 38176833)
3. Waksman R, Ajani AE, White L, Chan R, Bass B, Pichard AD, Satler LF, Kent KM, Torguson R, Deible R, Pinnow E, Lindsay J. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis, Circulation 2004;109:340-344. (Pubitemid 38133901)
4. Oliver LN, Buttner PG, Hobson H, Golledge J. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis. Int J Cardiol 2008;126:216-23. (Pubitemid 351611666)
5. Neumann FJ, Desmet W, Grube E, Brachmann J, Presbitero P, Rubartelli P, Mügge A, Pede FD, Füllgraf D, Aengevaeren W, Spedicato L, Popma J. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005;111:2107-11. (Pubitemid 40577906)
6. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, Feyter P, Vos J, Foley D, Ligthart J, Popma J, Serruys PW. Sirolimus-eluting stents for the treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003;41:184-9. (Pubitemid 36092181)
7. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Müller R, Regar E, Degertekin M, Ligthart J, Disco C, Backx B, Russell M. TAXUS III trial: instent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-64. (Pubitemid 36176804)
8. Saia F, Lemos PA, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Sianos G, Smits PC, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004;90:1183-8. (Pubitemid 39279907)
9. Worthley M, Todd A, Traboulsi M, Charbonneau F, Curtis M, Hansen J, Knudtson M, Spence F, Goodhart D. Registry Data Evaluating the Effectiveness of Drug Eluting Stents for the Treatment of Symptomatic In-stent Restenosis. Heart Lung Circ 2006;15:30-305.
10. Anderson RA, Fath-Ordoubadi F, Younsa S, Bainbridge A, Swallow RA, Dawkins KD, Curzen NP. Drug-eluting stents for the treatment of in-stent restenosis - 'real world' double centre experience in consecutive patients. Int J Cardiovasc Interv 2005;7:188 192.
11. Albiero R, Silber S, Di Mario C, Cernigliaro C, Battaglia S, Reimers B, Frasheri A, Klauss V, Auge J, Rubartelli P. RESCUT Investigators. Longterm results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol 2005;46:756-60. (Pubitemid 41224795)
12. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, Mc Garry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006;295:1253-1263.
13. Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within baremetal stents: the SISR randomized trial. JAMA 2006;295:1264-1273.
14. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-1436. (Pubitemid 27486458)
15. Goldberg SL, Loussararian A, De Gregorio J, Di Mario C, Albiero R, Colombo A. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol 2001;37:1019-1025. (Pubitemid 32217600)
16. Mercado N, Boersma E, Wijns W, Gersh BJ, Morillo CA, de Valk V, van Es GA, Grobbee DE, Serruys PW. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001;38:645-652. (Pubitemid 32835730)
17. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of instent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8. (Pubitemid 29511140)
18. Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, Chieffo A, Montorfano M, Cosgrave J, Michev I, Rogacka R, Sangiorgi G, Colombo A. Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary In-Stent Restenosis. Am J Cardiol 2006;97:1182-1187.
19. Park C, Hong M, Kim YA, Park DW, Han KH, Lee CW, Kang D, Song JK, Kim JJ, Park SW, Park SJ. Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent. Int J Cardiol 2007;120:387-90. (Pubitemid 47069565)
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors and outcomes of thrombosis after successful implantation of drug eluting stents. JAMA 2005;293:2126-2130. (Pubitemid 40617065)